Related Experiment Videos
Irreversible block of the mycelial-to-yeast phase transition of Histoplasma capsulatum
Abstract:
p-Chloromercuriphenylsulfonic acid (PCMS), a sulfhydryl inhibitor, prevented the mycelial-to-yeast transition of the dimorphic fungal pathogen, Histoplasma capsulatum. The effect of PCMS was specific for the mycelial-to-yeast transformation; it had no effect on growth of either the yeast or mycelial forms or on the yeast-to-mycelial transition. The failure of PCMS-treated mycelia to transform to yeast was permanent and irreversible. PCMS-treated mycelia could not infect mice but could stimulate resistance to infection by a pathogenic strain of Histoplasma capsulatum. These results suggest a new general strategy for vaccine development in diseases caused by dimorphic pathogens.
Insights
p-Chloromercuriphenylsulfonic acid (PCMS) irreversibly blocked the yeast transition in Histoplasma capsulatum. PCMS-treated fungi could not infect but induced resistance, suggesting a novel vaccine strategy for dimorphic pathogens.
Area of Science:
- Mycology
- Pathogen Biology
- Immunology
Background:
- Dimorphic fungal pathogens, like Histoplasma capsulatum, can switch between mycelial and yeast forms.
- This transition is crucial for fungal pathogenesis and infection.
- Understanding the mechanisms regulating this transition is key to developing new treatments.
Purpose of the Study:
- To investigate the effect of p-Chloromercuriphenylsulfonic acid (PCMS) on the dimorphic transition of Histoplasma capsulatum.
- To determine if PCMS could serve as a basis for novel anti-fungal strategies.
Main Methods:
- Treatment of Histoplasma capsulatum mycelia with p-Chloromercuriphenylsulfonic acid (PCMS).
- Assessment of the mycelial-to-yeast transition.
- Evaluation of fungal growth in both yeast and mycelial forms.
- Testing the infectivity of PCMS-treated fungi in a mouse model.
- Assessing the immunogenicity of PCMS-treated fungi.
Main Results:
- PCMS specifically and irreversibly inhibited the mycelial-to-yeast transition in Histoplasma capsulatum.
- PCMS did not affect the growth of yeast or mycelial forms, nor the yeast-to-mycelial transition.
- PCMS-treated mycelia were non-infectious in mice.
- PCMS-treated mycelia conferred resistance against subsequent infection by pathogenic Histoplasma capsulatum.
Conclusions:
- p-Chloromercuriphenylsulfonic acid is a potent inhibitor of the dimorphic transition in Histoplasma capsulatum.
- Inhibition of the dimorphic transition renders the fungus avirulent but immunogenic.
- This finding suggests a potential new vaccine development strategy for diseases caused by dimorphic fungal pathogens.